Celldex Therapeutics (CLDX +25%) goes on a tear today after reporting positive final results...


Celldex Therapeutics (CLDX +25%) goes on a tear today after reporting positive final results from Phase 2b studies of its breast cancer treatment CDX-011. Brean Capital was impressed, saying in a note to clients that the treatment "targets a clear and large unmet need," while Oppenheimer raised its price target from $6 to $8 and Jefferies from $7 to $9.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs